Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 47 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2014', provides an overview of the Exocrine Pancreatic Insufficiency's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Exocrine Pancreatic Insufficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Exocrine Pancreatic Insufficiency and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Exocrine Pancreatic Insufficiency
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Exocrine Pancreatic Insufficiency and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Exocrine Pancreatic Insufficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Exocrine Pancreatic Insufficiency pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Exocrine Pancreatic Insufficiency
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Exocrine Pancreatic Insufficiency pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Exocrine Pancreatic Insufficiency Overview 6
Therapeutics Development 7
Pipeline Products for Exocrine Pancreatic Insufficiency - Overview 7
Pipeline Products for Exocrine Pancreatic Insufficiency - Comparative Analysis 8
Exocrine Pancreatic Insufficiency - Therapeutics under Development by Companies 9
Exocrine Pancreatic Insufficiency - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Exocrine Pancreatic Insufficiency - Products under Development by Companies 13
Exocrine Pancreatic Insufficiency - Companies Involved in Therapeutics Development 14
Actavis plc 14
Anthera Pharmaceuticals� Inc. 15
Cilian AG 16
Laboratoires Mayoly Spindler S.A.S. 17
Nordmark Arzneimittel GmbH & Co. KG 18
Exocrine Pancreatic Insufficiency - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Drug Profiles 27
burlulipase - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Cilase - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Enzyme to Replace Lipase for Exocrine Pancreatic Insufficiency - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
liprotamase - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
MS-1819 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
pancrelipase DR - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Exocrine Pancreatic Insufficiency - Recent Pipeline Updates 36
Exocrine Pancreatic Insufficiency - Dormant Projects 38
Exocrine Pancreatic Insufficiency - Discontinued Products 39
Exocrine Pancreatic Insufficiency - Product Development Milestones 40
Featured News & Press Releases 40
Dec 10, 2012: Aptalis Pharma Announces US Commercial Availability Of Ultresa Delayed-release Capsules 40
Aug 01, 2012: Cilian Receives �1m Grant For Development Of Cilase 40
Mar 01, 2012: Aptalis Pharma Receives FDA Approval For ULTRESA Pancrelipase Delayed Release Capsules 40
Jul 14, 2011: Aptalis Pharma Receives FDA Approval Of 25,000 Lipase-Unit Strength Of ZENPEP 41
Jun 17, 2011: Aptalis Pharma Receives FDA Approval For New Low Strength Of ZENPEP 42
Apr 15, 2011: Lilly Receives Complete Response Letter From FDA For Liprotamase For Treatment Of Exocrine Pancreatic Insufficiency 42
Feb 11, 2011: Axcan Completes Acquisition of Eurand and Commences Subsequent Offering Period 43
Jan 12, 2011: Lilly Announces FDA Panel Recommendation For Liprotamase 43
Jan 12, 2011: Eurand Announces Agreement With Nycomed for ZENPEP in Russia-CIS 43
Oct 21, 2010: Eurand Presents Data On ZENPEP Without Proton Pump Inhibitors Or H2 Receptor Antagonists For Treatment Of Pancreatic Insufficiency 44
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables
Number of Products under Development for Exocrine Pancreatic Insufficiency, H2 2014 7
Number of Products under Development for Exocrine Pancreatic Insufficiency - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Exocrine Pancreatic Insufficiency - Pipeline by Actavis plc, H2 2014 14
Exocrine Pancreatic Insufficiency - Pipeline by Anthera Pharmaceuticals� Inc., H2 2014 15
Exocrine Pancreatic Insufficiency - Pipeline by Cilian AG, H2 2014 16
Exocrine Pancreatic Insufficiency - Pipeline by Laboratoires Mayoly Spindler S.A.S., H2 2014 17
Exocrine Pancreatic Insufficiency - Pipeline by Nordmark Arzneimittel GmbH & Co. KG, H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 24
Number of Products by Stage and Molecule Type, H2 2014 26
Exocrine Pancreatic Insufficiency Therapeutics - Recent Pipeline Updates, H2 2014 36
Exocrine Pancreatic Insufficiency - Dormant Projects, H2 2014 38
Exocrine Pancreatic Insufficiency - Discontinued Products, H2 2014 39